LINC00662 and prostate carcinoma: Consistently, LINC00662 has been shown to be overexpressed in many different tumors, including lung cancer, breast cancer, cervical cancer, prostate cancer, chordoma, glioma, gastric cancer, and hepatocellular carcinoma.